/etc.clientlibs/common/clientlibs/resources/svg/people-directory.svg
Disis
Mary (Nora) L. Disis, MD

Mary (Nora) L. Disis, MD

  • Professor, Clinical Research Division, Fred Hutch
206.685.3128

Background

Dr. Mary “Nora” Disis is an expert in the immunology and immunotherapy of breast and ovarian cancers. She is dedicated to translating lab discoveries into the clinic for patients and holds several patents for targeted cancer therapies and diagnostics. Dr. Disis’ research interest lies in the discovery of new molecular targets for cancer immunotherapies, particularly vaccines and T-cell therapies. She is one of the investigators who discovered that the molecule HER-2/neu is a tumor-specific marker, or antigen. Today, many widely used cancer drugs target HER-2, and her work has led to several clinical trials testing HER-2–based cancer vaccines. Her group also studies how the immune system could be used to diagnose cancer and develops novel tests for characterizing the immune system. In addition to her research and clinical work, Dr. Disis holds many local and national leadership positions in her field.

Find an Active Clinical Trial Led by Dr. Disis

Stories

All news
Breast Cancer Research Foundation to fund seven Cancer Consortium researchers BCRF awards $2.6M in grants to Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium researchers December 10, 2025
$600,000 in awards against ovarian cancer for Fred Hutch and UW researchers Research awarded from the Rivkin Center and Andy Hill CARE fund will dramatically improve outcomes for ovarian cancer patients and the clinicians treating them April 11, 2025
New funding drives six breast cancer studies Scientists from Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium receive $1.7M in grants from Breast Cancer Research Foundation November 4, 2024